1. Home
  2. MPLT vs BHVN Comparison

MPLT vs BHVN Comparison

Compare MPLT & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$28.57

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Biohaven Ltd.

BHVN

Biohaven Ltd.

HOLD

Current Price

$9.47

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPLT
BHVN
Founded
2018
2013
Country
United States
United States
Employees
133
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
MPLT
BHVN
Price
$28.57
$9.47
Analyst Decision
Strong Buy
Buy
Analyst Count
7
14
Target Price
$32.67
$29.08
AVG Volume (30 Days)
253.4K
1.7M
Earning Date
05-28-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.08
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.24
$7.48
52 Week High
$33.28
$18.57

Technical Indicators

Market Signals
Indicator
MPLT
BHVN
Relative Strength Index (RSI) 52.37 51.14
Support Level $26.70 $9.26
Resistance Level $32.23 $10.57
Average True Range (ATR) 2.34 0.66
MACD -0.40 0.00
Stochastic Oscillator 58.24 49.41

Price Performance

Historical Comparison
MPLT
BHVN

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.

Share on Social Networks: